Guides strategic IT decisions by clarifying trade-offs between cloud and on-premise solutions, to align infrastructure strategy with agility, security, and compliance objectives.
Explore practical strategies for scaling AI implementation across clinical development pipelines, enabling faster trial execution, smarter protocol design, and improved patient recruitment while aligning with evolving regulatory expectations.
Maria Florez
Senior Consultant
Tufts
- Explore how AI models predict protein 3D structures from sequences, enabling insights into folding pathways and functional conformations
- Examine foundational models that reveal protein–protein interactions and guide design of innovative drug candidates
Miles Congreve
Chief Scientific Officer
Isomorphic Labs
Learn how AI-driven approaches integrate multiomics data, including genomics, proteomics, and transcriptomics, to identify potential drug targets and disease biomarkers for complex diseases.
Explore how AI models synthesize cross-omic data and real-time multiomic information to uncover novel biological mechanisms, identify potential biomarkers and enable precision medicine.
Moderator
Eva Fast
Senior Principal Computational Biologist
Pfizer
Kiran Nistala
Head, Functional Genomics
Alkermes
Harris Bell-Temin
Director, Proteomics
Johnson & Johnson Innovative Medicine
Moderator
David Champagne
Senior Partner
McKinsey & Company
Melissa Landon
Head, Commercial & Business Development, AI & Automation
MilliporeSigma
David Hallett
Chief Scientific Officer
Recursion
Morten Sogaard
Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma
Peter Clark
Vice President, Digital Chemistry & Design
Novo Nordisk RDUS
MilliporeSigma
Website: https://www.sigmaaldrich.com
Together with our colleagues, customers and stakeholders, we impact life and health with science. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services and expertise to perform experiments and engineer new products. That’s where we come in.
We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities.
Our vision is a world where our innovative products, services and digital offerings help create solutions for people globally and a sustainable future for generations to come.
The life science business of Merck KGaA, Darmstadt, Germany, operates as MilliporeSigma in the US and Canada. Merck KGaA, Darmstadt, Germany is a global science and technology company with around 60,000 employees in more than 66 countries.
Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization.
Learn how predictive simulations, generative AI and differentiating clinical biomarkers are forecasted to cut prototyping timelines by weeks and reduce per‑trial costs.
.
Gregory Goldmacher
Assistant Vice President, Clinical Research, Head, Imaging
Merck
Hitesh Seth
Chief Architect, Financial Services and Insurance
Salesforce
At Salesforce, Hitesh is responsible for the end-to-end architecture of platforms delivered to financial services and insurance clients globally. His focus is on working with key strategic customers to align Salesforce implementations with their business goals, particularly around the conjunction of Data+AI and CRM. This involves collaborating with retail and commercial banking, payments, wealth management, investment banking, insurance, and capital markets to influence product roadmaps and shape the future of technology in these industries. A significant part of Hitesh's role includes facilitating discussions with CTOs, CIOs, CDOs, and Chief Architects to: • Analyze current architectures and design target states. • Optimize Salesforce technologies for customer needs. • Integrate and Interoperate with Salesforce platforms within broader ecosystems. Being the executive sponsors for the customers, I play a key role in influencing product development within Salesforce by advocating for customer-driven innovations.
Hitesh oversees end-to-end platform and solution architecture for global financial services and insurance clients. He specializes in aligning Salesforce solutions with strategic business objectives, particularly at the intersection of Data+AI and CRM. By collaborating with retail and commercial banking, payments, wealth management, investment banking, insurance, and capital markets, Hitesh helps influence product roadmaps and shape the future of technology in these industries.
A key part of his role involves engaging CTOs, CIOs, CDOs, and Chief Architects to analyze current architectures, design target states, and optimize Salesforce within broader ecosystems. As an executive sponsor, Hitesh champions customer-driven innovation, ensuring product development meets evolving industry needs.
Sandeep Menon
Chief Development Officer
Alnylam
Empowers strategic R&D with AI-driven predictive modelling early in discovery, fostering a data-driven culture.
Learn how GenAI is transforming early drug discovery by designing novel, drug-like small molecules with improved potency, selectivity, and ADME properties.
Explore how GenAI integrates with synthesis planning and automation tools to prioritize viable candidates and accelerate iterative drug development.
Moderator
Jason Shields
Associate Principal Scientist
AstraZeneca
Christopher D. Taylor
Director of Applied Sciences
Promethium (QC Ware Corp.)
Christopher D. Taylor is Director of Applied Sciences at Promethium (QC Ware Corp.), bringing over 25 years of expertise in density functional theory (DFT). He works with drug discovery teams to bridge AI and quantum chemistry, guiding the deployment of DFT-based rational drug design and descriptor-driven frameworks for drug discovery. Throughout his career, Christopher has used DFT to solve problems once considered unsolvable, and he now highlights how high-quality quantum mechanical data, when used to train AI models, delivers significant gains in accuracy and insight. By translating complex scientific challenges into scalable workflows, he helps accelerate both small molecule and macromolecule design with quantum-level precision.
Philip Tagari
Chief Scientific Officer
Insitro
Yue-Wang Webster
Vice President, Model Driven Drug Discovery Platforms
Eli Lilly
QC Ware
Website: https://www.qcware.com/
Promethium is a GPU-native, first-principles quantum mechanics (QM) simulation platform developed by QC Ware to accelerate small-molecule drug discovery. Built for both speed and accuracy, Promethium runs up to 100× faster than traditional DFT tools while maintaining quantum-level precision.
Its unique ability to rank-order ligands within 5-25 minutes per compound, delivering FEP-like accuracy, gives medicinal and computational chemists a powerful way to prioritize hits, refine leads, and explore chemical space with unprecedented efficiency. Promethium empowers pharma R&D teams to make faster, more confident decisions in lead optimization and beyond.
Discuss how AI is used to identify pathological features, discover drug targets, and decode complex disease biology at a systems level.
Casandra Mangroo
SVP, Strategic Alliances
BenchSci
Ari Allyn-Feuer
Director, AI Intelligence Product
GSK
Arvind Rao
Professor, Computational Medicine & Bioinformatics
University of Michigan
BenchiSci
Website: https://www.benchsci.com/
BenchSci is a world leader in AI solutions for preclinical R&D. Using proprietary technology, we help decode the complexity of biomedical research.